{
  "trial_id": "NCT00063882",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Performance status (Zubrod score), Gleason score, Prostate-specific antigen (PSA) level, Prostate volume, American Urological Association voiding symptom score, Prior neoadjuvant hormonal therapy, Use of 5-alpha reductase inhibitors, History of other malignancies, Presence of major medical or psychiatric illness, Presence of hip prosthesis, Prior chemotherapy, Prior pelvic radiotherapy, Prior radical surgery for prostate cancer, Prior transurethral resection of the prostate, Prior cryosurgery, Prior transurethral needle ablation of the prostate, Prior transurethral microwave thermotherapy of the prostate.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Zubrod Performance Status",
          "Performance status (Zubrod score)"
        ],
        [
          "Gleason Score & PSA",
          "Gleason score"
        ],
        [
          "Baseline Prostate Specific Antigen (PSA)",
          "Prostate-specific antigen (PSA) level"
        ],
        [
          "Neoadjuvant Hormone Therapy",
          "Prior neoadjuvant hormonal therapy"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Combined Gleason Score (GS)",
        "T Stage"
      ],
      "remaining_candidate_features": [
        "Prostate volume",
        "American Urological Association voiding symptom score",
        "Use of 5-alpha reductase inhibitors",
        "History of other malignancies",
        "Presence of major medical or psychiatric illness",
        "Presence of hip prosthesis",
        "Prior chemotherapy",
        "Prior pelvic radiotherapy",
        "Prior radical surgery for prostate cancer",
        "Prior transurethral resection of the prostate",
        "Prior cryosurgery",
        "Prior transurethral needle ablation of the prostate",
        "Prior transurethral microwave thermotherapy of the prostate"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Gleason Score, Prostate-Specific Antigen (PSA) Level, Prostate Volume, American Urological Association (AUA) Voiding Symptom Score, Performance Status (Zubrod), Prior Neoadjuvant Hormonal Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Baseline Prostate Specific Antigen (PSA)",
          "Prostate-Specific Antigen (PSA) Level"
        ],
        [
          "Zubrod Performance Status",
          "Performance Status (Zubrod)"
        ],
        [
          "Gleason Score & PSA",
          "Gleason Score"
        ],
        [
          "Neoadjuvant Hormone Therapy",
          "Prior Neoadjuvant Hormonal Therapy"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Ethnicity (NIH/OMB)",
        "Combined Gleason Score (GS)",
        "T Stage"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Prostate Volume",
        "American Urological Association (AUA) Voiding Symptom Score"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Prostate Volume, Gleason Score, Prostate-Specific Antigen (PSA), American Urological Association Voiding Symptom Score, Zubrod Performance Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Baseline Prostate Specific Antigen (PSA)",
          "Prostate-Specific Antigen (PSA)"
        ],
        [
          "Zubrod Performance Status",
          "Zubrod Performance Status"
        ],
        [
          "Combined Gleason Score (GS)",
          "Gleason Score"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Gleason Score & PSA",
        "T Stage",
        "Neoadjuvant Hormone Therapy"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Prostate Volume",
        "American Urological Association Voiding Symptom Score"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, Performance status (Zubrod score), Prostate volume, Gleason score, Prostate-specific antigen (PSA) level, American Urological Association voiding symptom score, Tumor stage (T1c-T2b), Nodal status (N0), Metastatic status (M0).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Zubrod Performance Status",
          "Performance status (Zubrod score)"
        ],
        [
          "Baseline Prostate Specific Antigen (PSA)",
          "Prostate-specific antigen (PSA) level"
        ],
        [
          "Combined Gleason Score (GS)",
          "Gleason score"
        ],
        [
          "T Stage",
          "Tumor stage (T1c-T2b)"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Neoadjuvant Hormone Therapy"
      ],
      "remaining_candidate_features": [
        "Prostate volume",
        "American Urological Association voiding symptom score",
        "Nodal status (N0)",
        "Metastatic status (M0)"
      ]
    }
  }
}